Recombinant Romiplostim
Immune Thrombocytopenia
Pre-clinicalActive
Key Facts
Indication
Immune Thrombocytopenia
Phase
Pre-clinical
Status
Active
About Paras Biopharmaceuticals Finland
Paras Biopharmaceuticals is a private, pre-revenue Finnish biotech focused on developing biosimilars and proprietary microbial expression technologies. The company operates a three-pronged business model encompassing a microbial biologics CDMO service, biosimilar technology development partnerships, and the sale of recombinant bioprocess enzymes. With a suite of proprietary platforms like Diabrid®, NobleCleav®, and Biomultifold®, Paras aims to enable cost-effective, high-yield production of complex therapeutic proteins and peptides. It is actively seeking partners to advance its pipeline of biosimilar candidates for osteoporosis, rheumatoid arthritis, and other conditions.
View full company profile